N1-(4-piperidinylmethyl)-1,2-ethanediamine | 71172-94-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N1-(4-piperidinylmethyl)-1,2-ethanediamine
• 英文别名: N'-(piperidin-4-ylmethyl)ethane-1,2-diamine
• CAS: 71172-94-6
• 化学式: C₈H₁₉N₃
• 分子量: 157.26
• InChiKey: VOOQJHYXJMACQI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  50.1
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• SUCCINOYLAMINO HETEROCYCLES AS INHIBITORS OF A-BETA PROTEIN PRODUCTION
  申请人：Bristol-Myers Squibb Pharma Company

  公开号：EP1268454A1

  公开（公告）日：2003-01-02
• Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents
  申请人：Baures Paul W.

  公开号：US20100222356A1

  公开（公告）日：2010-09-02

  The present invention provides novel compounds and pharmaceutical compositions thereof, as well as methods for using the compounds and pharmaceutical compositions for treating tumors. Examples of specific tumor types that the compounds may be used to treat include, but are not limited to sarcomas, melanomas, neuroblastomas, carcinomas (including but not limited to lung, renal cell, ovarian, liver, bladder, and pancreatic carcinomas), and mesotheliomas.
• [EN] SUCCINOYLAMINO HETEROCYCLES AS INHIBITORS OF A beta PROTEIN PRODUCTION<br/>[FR] HETEROCYCLES SUCCINOYLAMINO EN TANT QU'INHIBITEURS DE LA PRODUCTION DE LA BETA-PROTEINE
  申请人：DU PONT PHARM CO

  公开号：WO2001074796A1

  公开（公告）日：2001-10-11

  This invention relates to a novel succinoylamino heterocycles of Formula (I) having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.
• [EN] CARBAPENEM COMPOUNDS<br/>[FR] COMPOSÉS DE CARBAPÉNÈME
  申请人：ORCHID PHARMA LTD

  公开号：WO2017158616A1

  公开（公告）日：2017-09-21

  This invention relates to carbapenem compounds, their stereoisomers, pharmaceutically acceptable salts or N-oxides thereof, which may be useful for the treatment of bacterial infections, particularly drug-resistant bacterial infections, as well as the processes for the preparation of compounds, the pharmaceutical compositions of these compounds and their use in the treatment of bacterial infection.